Novel nanomedicines to overcome cancer multidrug resistance

Z Su, S Dong, SC Zhao, K Liu, Y Tan, X Jiang… - Drug Resistance …, 2021 - Elsevier
Chemotherapy remains a powerful tool to eliminate malignant cells. However, the efficacy of
chemotherapy is compromised by the frequent emergence of intrinsic and acquired …

Strategies and lessons learned from total synthesis of taxol

L Min, JC Han, W Zhang, CC Gu, YP Zou… - Chemical …, 2023 - ACS Publications
Taxol (paclitaxel), the most well-known taxane diterpenoid, is the best-selling natural-source
anticancer drug ever produced and one of the most common prescriptions in the treatment of …

Therapeutic strategies to overcome taxane resistance in cancer

T Das, U Anand, SK Pandey, CR Ashby Jr… - Drug Resistance …, 2021 - Elsevier
One of the primary causes of attenuated or loss of efficacy of cancer chemotherapy is the
emergence of multidrug resistance (MDR). Numerous studies have been published …

Triple negative breast cancer treatment options and limitations: future outlook

O Obidiro, G Battogtokh, EO Akala - Pharmaceutics, 2023 - mdpi.com
Triple negative breast cancer (TNBC) has a negative expression of estrogen receptors (ER),
progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The …

Long non-coding RNA mediated drug resistance in breast cancer

D Singh, YG Assaraf, RN Gacche - Drug Resistance Updates, 2022 - Elsevier
Breast cancer is one of the most prevalent cancers in women and a leading cause of
mortality. As per the GLOBCAN report of 2021, breast cancer has surpassed lung cancer …

Curcumin as an enhancer of therapeutic efficiency of chemotherapy drugs in breast cancer

R Farghadani, R Naidu - International Journal of Molecular Sciences, 2022 - mdpi.com
Female breast cancer is the world's most prevalent cancer in 2020. Chemotherapy still
remains a backbone in breast cancer therapy and is crucial in advanced and metastatic …

Chemopreventive effects of hesperidin against paclitaxel-induced hepatotoxicity and nephrotoxicity via amendment of Nrf2/HO-1 and caspase-3/Bax/Bcl-2 signaling …

C Gur, FM Kandemir, C Caglayan, E Satıcı - Chemico-biological …, 2022 - Elsevier
Paclitaxel (PTX) is a widely used chemotherapeutic drug particularly effective against lung,
breast, and ovarian cancer, though its usefulness is limited due to its multi-organ toxicity …

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors

X Du, B Yang, Q An, YG Assaraf, X Cao, J Xia - The Innovation, 2021 - cell.com
The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies

Y Li, C Xu, B Wang, F Xu, F Ma, Y Qu, D Jiang… - Nature …, 2022 - nature.com
Chemotherapy and targeted therapy are the major treatments for gastric cancer (GC), but
drug resistance limits its effectiveness. Here, we profile the proteome of 206 tumor tissues …

Paclitaxel resistance related to nuclear envelope structural sturdiness

ER Smith, JQ Wang, DH Yang, XX Xu - Drug Resistance Updates, 2022 - Elsevier
Abstract Taxanes (Taxol/paclitaxel, Docetaxel/taxotere) are a key group of successful drugs
commonly used in chemotherapy to treat several major malignant tumors also as a front-line …